Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
April 17, 2024 08:00 ET
|
Recce Pharmaceuticals
Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaignR327 manufactured under GMP standards in support of current and anticipated clinical...
Recce Pharmaceuticals Provides Business Update
April 10, 2024 08:00 ET
|
Recce Pharmaceuticals
Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several...
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
April 09, 2024 20:00 ET
|
Recce Pharmaceuticals
Recce recognized by the United Kingdom Government Innovation Agency among the most promising organizations for the UK AMR Inward Mission 2024Recce chosen as one of 18 organizations globally for its...
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
April 04, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State...
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
March 22, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, March 22, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it has been...
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
March 19, 2024 08:00 ET
|
Recce Pharmaceuticals
Four healthy subjects dosed with RECCE® 327 at 3,000mg over 20 minutesData received from this cohort will support preparations for a Phase II trial SYDNEY, Australia, March 19, 2024 (GLOBE...
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
March 14, 2024 08:00 ET
|
Recce Pharmaceuticals
The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming daysRECCE® 327 now tested at four infusion times, achieving these...
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
March 13, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a...
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
March 12, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced...
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute
February 29, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced...